Loading...
Market
Significant drop in Tagrisso sales due to RYBREVANT and LAZCLUZE by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
AstraZeneca's financial reports and sales data
Story
Johnson & Johnson's RYBREVANT and LAZCLUZE Outperform Tagrisso, Promising Over One Year Survival Improvement Over Osimertinib
Jan 7, 2025, 01:11 PM
Johnson & Johnson announced that its lung cancer treatment, a combination of RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib), has shown a statistically significant and clinically meaningful improvement in overall survival compared to osimertinib. In a head-to-head study, this combination therapy outperformed AstraZeneca’s Tagrisso, which could potentially alter the standard of care for lung cancer, one of the most lethal tumor types. The company indicated that the median overall survival improvement is expected to exceed one year.
View original story
Similar markets
10% to 20% • 25%
More than 30% • 25%
Less than 10% • 25%
21% to 30% • 25%
Increase by more than 20% • 25%
No significant increase • 25%
Increase by less than 10% • 25%
Increase between 10% and 20% • 25%
Second • 25%
Lower • 25%
Leading • 25%
Third • 25%
Kisqali (ribociclib) • 25%
Enhertu (trastuzumab deruxtecan) • 25%
Verzenio (abemaciclib) • 25%
Other • 25%
No • 50%
Yes • 50%
Less than 10% • 25%
More than 30% • 25%
20-30% • 25%
10-20% • 25%
No significant change • 25%
Other outcome • 25%
Alcon gains market share • 25%
Alcon loses market share • 25%
No Change • 25%
Worse Outcomes • 25%
Significant Improvement • 25%
Moderate Improvement • 25%
More than $2 billion • 25%
$1 billion to $2 billion • 25%
$500 million to $1 billion • 25%
Less than $500 million • 25%